VRTXVRTX: Daniel Brennan Joins Board & Audit Committee
Vertex (VRTX) appoints Daniel Brennan to its board and Audit & Finance Committee, adding oversight amid CF franchise growth, CASGEVY launch, Crinetics deal and recent CFO hire.
VERTEX PHARMACEUTICALS INC / MA
VRTXVertex Names Jonathan Poole as CFO
Vertex (VRTX) appoints Jonathan Poole as CFO, replacing Charles Wagner Jr., announced 2026-09-01. Investor context on finances, strategy, risks and acquisition.
VERTEX PHARMACEUTICALS INC / MA
VRTXVertex to Acquire Crinetics at $85/Share
Vertex (VRTX) announces merger to acquire Crinetics at $85/share on 2026-07-06. Deal aligns with Vertex's strategy to expand beyond its cystic fibrosis franchise.
VERTEX PHARMACEUTICALS INC / MA